Liminatus Pharma SG&A Expenses 2025-2025 | LIMN

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Liminatus Pharma sg&a expenses from 2025 to 2025. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Liminatus Pharma sg&a expenses from 2025 to 2025. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$81.3B
Zoetis (ZTS)	$67.2B
Daiichi Sankyo, - (DSNKY)	$46.3B
Takeda Pharmaceutical (TAK)	$45.6B
BeOne Medicines - (ONC)	$33.5B
Sandoz Group AG (SDZNY)	$26B
Summit Therapeutics (SMMT)	$19.9B
Merck (MKKGY)	$16.9B
Shionogi (SGIOY)	$14.3B
United Therapeutics (UTHR)	$13.4B
Neurocrine Biosciences (NBIX)	$13.3B
Orion OYJ (ORINY)	$11.4B
IPSEN (IPSEY)	$10.8B
Stevanato Group S.p.A (STVN)	$7.7B
Corcept Therapeutics (CORT)	$7.2B
Grifols, S.A (GRFS)	$7.2B
Ionis Pharmaceuticals (IONS)	$6.6B
Madrigal Pharmaceuticals (MDGL)	$6.5B
Hikma Pharmaceuticals Plc (HKMPF)	$6.2B
Ono Pharmaceutical (OPHLF)	$5.2B
Soleno Therapeutics (SLNO)	$4.2B
Hypermarcas (HYPMY)	$3B
Crinetics Pharmaceuticals (CRNX)	$2.7B
Catalyst Pharmaceuticals (CPRX)	$2.6B
NewAmsterdam Pharma (NAMS)	$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.5B
Centessa Pharmaceuticals (CNTA)	$2B
Ocular Therapeutix (OCUL)	$1.9B
Endo (NDOI)	$1.8B
ARS Pharmaceuticals (SPRY)	$1.7B